Loading...

Trever Bivona, MD, PhD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address600 16th St
San Francisco CA 94158
Phone415-476-9907
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    New York University School of MedicineM.D.2005School of Medicine
    New York University School of MedicinePh.D.2004Cell and Molecular Biology
    Brigham and Women's Hospital/Harvard2007Internal Medicine
    Memorial Sloan Kettering Cancer Center2011Medical Oncology and cancer biology post-doctoral fellowship

    Collapse Research 
    Collapse Research Activities and Funding
    (PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules
    NIH/NCI R01CA231300Jul 1, 2019 - Jun 30, 2024
    Role: Principal Investigator
    Bay Area Team Against Resistance
    NIH/NCI U54CA224081Sep 30, 2017 - Aug 31, 2022
    Role: Principal Investigator
    The Cancer Target Discovery and Development Network at UCSF
    NIH/NCI U01CA217882Aug 10, 2017 - Jul 31, 2022
    Role: Co-Principal Investigator
    Characterization of YAP as a rational companion target in lung cancer
    NIH/NCI R01CA204302Mar 1, 2017 - Feb 28, 2022
    Role: Principal Investigator
    Optimizing biologically-based rational polytherapy in ALK+ lung cancer
    NIH/NCI R01CA211052Jan 11, 2017 - Dec 31, 2021
    Role: Principal Investigator
    Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment
    NIH/NCI R01CA169338Feb 1, 2013 - Jan 31, 2024
    Role: Principal Investigator
    Discovery of Rational Companion Therapeutic Targets to Optimize Cancer Treatment
    NIH/NCI DP2CA174497Sep 15, 2012 - Aug 31, 2017
    Role: Principal Investigator
    Genetic Modifiers such as Fas Regulate Tumor-Cell Dependence on Mutant EGFR
    NIH/NCI K08CA154787Sep 21, 2011 - Aug 31, 2016
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse In The News
    Collapse Student Projects

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. 2020 Aug 07. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG. PMID: 32822576.
      View in: PubMed   Mentions:    Fields:    
    2. Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Nat Commun. 2020 Jul 22; 11(1):3675. Cao W, Lee H, Wu W, Zaman A, McCorkle S, Yan M, Chen J, Xing Q, Sinnott-Armstrong N, Xu H, Sailani MR, Tang W, Cui Y, Liu J, Guan H, Lv P, Sun X, Sun L, Han P, Lou Y, Chang J, Wang J, Gao Y, Guo J, Schenk G, Shain AH, Biddle FG, Collisson E, Snyder M, Bivona TG. PMID: 32699215.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. J Thorac Oncol. 2020 Jun 13. Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE. PMID: 32540409.
      View in: PubMed   Mentions:    Fields:    
    4. EGFR targeted therapy resistance: current status, challenges, and future outlook. J Thorac Dis. 2020 May; 12(5):2849-2850. Bivona TG. PMID: 32642197.
      View in: PubMed   Mentions:
    5. Betacellulin drives therapy resistance in glioblastoma. Neuro Oncol. 2020 04 15; 22(4):457-469. Fan Q, An Z, Wong RA, Luo X, Lu ED, Baldwin A, Mayekar MK, Haderk F, Shokat KM, Bivona TG, Weiss WA. PMID: 31678994.
      View in: PubMed   Mentions:    Fields:    
    6. AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun; 15(6):973-999. Lotsberg ML, Wnuk-Lipinska K, Terry S, Tan TZ, Lu N, Trachsel-Moncho L, Røsland GV, Siraji MI, Hellesøy M, Rayford A, Jacobsen K, Ditzel HJ, Vintermyr OK, Bivona TG, Minna J, Brekken RA, Baguley B, Micklem D, Akslen LA, Gausdal G, Simonsen A, Thiery JP, Chouaib S, Lorens JB, Engelsen AST. PMID: 32018052.
      View in: PubMed   Mentions: 1     Fields:    
    7. Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy. Chronic Dis Transl Med. 2019 Dec; 5(4):258-266. Zargar A, Chang S, Kothari A, Snijders AM, Mao JH, Wang J, Hernández AC, Keasling JD, Bivona TG. PMID: 32055785.
      View in: PubMed   Mentions:
    8. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 01 15; 26(2):439-449. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. PMID: 31548343.
      View in: PubMed   Mentions: 2     Fields:    
    9. BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. Cancers (Basel). 2019 Sep 17; 11(9). Bracht JWP, Karachaliou N, Bivona T, Lanman RB, Faull I, Nagy RJ, Drozdowskyj A, Berenguer J, Fernandez-Bruno M, Molina-Vila MA, Rosell R. PMID: 31533235.
      View in: PubMed   Mentions:
    10. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Cell Rep. 2019 08 27; 28(9):2317-2330.e8. Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG. PMID: 31461649.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    11. Targeting Oncogenic BRAF: Past, Present, and Future. Cancers (Basel). 2019 Aug 16; 11(8). Zaman A, Wu W, Bivona TG. PMID: 31426419.
      View in: PubMed   Mentions:
    12. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. J Clin Invest. 2019 07 22; 129(8):3401-3406. Okimoto RA, Wu W, Nanjo S, Olivas V, Lin YK, Ponce RK, Oyama R, Kondo T, Bivona TG. PMID: 31329165.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    13. Engineering Multidimensional Evolutionary Forces to Combat Cancer. Cancer Discov. 2019 05; 9(5):587-604. McCoach CE, Bivona TG. PMID: 30992280.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    14. Dampening oncogenic RAS signaling. Science. 2019 03 22; 363(6433):1280-1281. Bivona TG. PMID: 30898918.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    15. Polytherapy and Targeted Cancer Drug Resistance. Trends Cancer. 2019 03; 5(3):170-182. Chatterjee N, Bivona TG. PMID: 30898264.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Curr Oncol Rep. 2019 02 26; 21(3):21. Halliday PR, Blakely CM, Bivona TG. PMID: 30806814.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    17. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. J Exp Med. 2019 02 04; 216(2):419-427. Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR. PMID: 30683736.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCTClinical Trials
    18. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019 03; 25(3):185-197. Sabnis AJ, Bivona TG. PMID: 30686761.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    19. Immunohistochemistry to Study YAP in Human Tissue Samples. Methods Mol Biol. 2019; 1893:89-95. Haderk F, Olivas V, Bivona TG. PMID: 30565127.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    20. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Res. 2019 02 01; 79(3):546-556. Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG. PMID: 30538120.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    21. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019 01; 25(1):111-118. Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. PMID: 30478424.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    22. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clin Lung Cancer. 2019 03; 20(2):e137-e141. Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. PMID: 30553716.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    23. Circulating tumor DNA analysis in patients with EGFR mutant lung cancer. J Thorac Dis. 2018 Nov; 10(Suppl 33):S4061-S4064. Nanjo S, Bivona TG. PMID: 30631555.
      View in: PubMed   Mentions:
    24. Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci. 2018 09 05; 131(17). Sannino S, Guerriero CJ, Sabnis AJ, Stolz DB, Wallace CT, Wipf P, Watkins SC, Bivona TG, Brodsky JL. PMID: 30131440.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    25. Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Science. 2018 08 31; 361(6405). Bugaj LJ, Sabnis AJ, Mitchell A, Garbarino JE, Toettcher JE, Bivona TG, Lim WA. PMID: 30166458.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    26. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018 09; 20(9):1064-1073. Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG. PMID: 30104724.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    27. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018 09; 13(9):1248-1268. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. PMID: 29885479.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    28. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest. 2018 06 01; 128(6):2500-2518. Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA. PMID: 29613856.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    29. Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. Ann Transl Med. 2018 May; 6(9):160. Zaman A, Bivona TG. PMID: 29911108.
      View in: PubMed   Mentions:
    30. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 04 05; 173(2):321-337.e10. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. PMID: 29625050.
      View in: PubMed   Mentions: 134     Fields:    Translation:HumansCells
    31. The evolving understanding of immunoediting and the clinical impact of immune escape. J Thorac Dis. 2018 Mar; 10(3):1248-1252. McCoach CE, Bivona TG. PMID: 29708132.
      View in: PubMed   Mentions:
    32. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine. 2018 03; 29:112-127. Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, Capitan AG, Rodriguez J, Rojas L, Viteri S, Molina-Vila MA, Ou SI, Okada M, Mok TS, Bivona TG, Ono M, Cui J, Ramón Y Cajal S, Frias A, Cao P, Rosell R. PMID: 29433983.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    33. Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. Cancers (Basel). 2017 Nov 30; 9(12). Wu W, Haderk F, Bivona TG. PMID: 29189709.
      View in: PubMed   Mentions:
    34. Imaging PD-L1 Expression with ImmunoPET. Bioconjug Chem. 2018 01 17; 29(1):96-103. Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. PMID: 29125731.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    35. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. PMID: 29106415.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    36. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017 10 25; 17(11):637-658. Rotow J, Bivona TG. PMID: 29068003.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimals
    37. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat Commun. 2017 10 10; 8(1):823. Ma P, Fu Y, Cai MC, Yan Y, Jing Y, Zhang S, Chen M, Wu J, Shen Y, Zhu L, Chen HZ, Gao WQ, Wang M, Gu Z, Bivona TG, Zhao X, Zhuang G. PMID: 29018192.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    38. Current Landscape of Targeted Therapy in Lung Cancer. Clin Pharmacol Ther. 2017 Nov; 102(5):757-764. Mayekar MK, Bivona TG. PMID: 28786099.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    39. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun. 2017 09 04; 8(1):410. Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R. PMID: 28871105.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    40. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. J Natl Cancer Inst. 2017 09 01; 109(9). Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, Passaro A, Carcereny E, Reguart N, Campelo CG, Teixido C, Sperduti I, Rodriguez S, Lazzari C, Verlicchi A, de Aguirre I, Queralt C, Wei J, Estrada R, Puig de la Bellacasa R, Ramirez JL, Jacobson K, Ditzel HJ, Santarpia M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R. PMID: 28376152.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    41. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). Oncotarget. 2017 Jul 18; 8(29):47305-47316. Codony-Servat C, Codony-Servat J, Karachaliou N, Molina MA, Chaib I, Ramirez JL, de Los Llanos Gil M, Solca F, Bivona TG, Rosell R. PMID: 28521301.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    42. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. Oncologist. 2017 07; 22(7):768-773. Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK. PMID: 28507205.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    43. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. NPJ Precis Oncol. 2017; 1. Neel DS, Bivona TG. PMID: 29152593.
      View in: PubMed   Mentions:
    44. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep. 2017 03 13; 7:44206. Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG. PMID: 28287179.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    45. Dividing and conquering the variation among variants in EML4-ALK lung cancer. Transl Cancer Res. 2017 Mar; 6(Suppl 2):S369-S370. Bivona TG. PMID: 30613480.
      View in: PubMed   Mentions:
    46. CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays. J Thorac Oncol. 2017 02; 12(2):e19-e20. Wang V, Bivona T, Ali SM, Schrock AB, Miller VA. PMID: 28115114.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    47. Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer. Cancer Res. 2017 03 01; 77(5):1200-1211. Rho JK, Lee IY, Choi YJ, Choi CM, Hur JY, Koh JS, Lee J, Suh BC, Song HJ, Salgaonkar P, Lee J, Lee J, Jung DS, Kim SY, Woo DC, Baek IJ, Lee JY, Ha CH, Sung YH, Kim JK, Kim WS, Song JS, Kim CH, Bivona TG, Lee JC. PMID: 28082405.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    48. Metastasis: From head to tail. Cell Cycle. 2017 03 19; 16(6):487-488. Okimoto RA, Bivona TG. PMID: 28055306.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    49. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFß2-bioenergetics-mitochondrial priming. Oncotarget. 2016 Dec 13; 7(50):82013-82027. Thiagarajan PS, Wu X, Zhang W, Shi I, Bagai R, Leahy P, Feng Y, Veigl M, Lindner D, Danielpour D, Yin L, Rosell R, Bivona TG, Zhang Z, Ma PC. PMID: 27852038.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    50. Inactivation of Capicua drives cancer metastasis. Nat Genet. 2017 01; 49(1):87-96. Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG. PMID: 27869830.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    51. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016 11 22; 113(47):13456-13461. Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG. PMID: 27834212.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    52. HSP70 dependence in rhabdomyosarcoma: Seed or soil? Cell Cycle. 2017 01 17; 16(2):147-148. Sabnis AJ, Bivona TG. PMID: 27686974.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    53. Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2016 08 09; 113(32):9015-20. Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona TG. PMID: 27450084.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    54. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 09 28; 380(1):144-52. Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. PMID: 27343980.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    55. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clin Lung Cancer. 2016 09; 17(5):466-469. McCoach CE, Bivona TG, Blakely CM, Doebele RC. PMID: 27378174.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    56. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat Med. 2016 05 05; 22(5):472-8. Bivona TG, Doebele RC. PMID: 27149220.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    57. RAS signaling in ALK fusion lung cancer. Small GTPases. 2016; 7(1):32-3. Hrustanovic G, Bivona TG. PMID: 26901483.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    58. Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discov. 2016 Jan; 6(1):14-6. Okimoto RA, Bivona TG. PMID: 26747892.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    59. RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer. Mol Cell Oncol. 2016 Mar; 3(2):e1091061. Hrustanovic G, Bivona TG. PMID: 27308613.
      View in: PubMed   Mentions:
    60. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. PMID: 26301689.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    61. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. PMID: 26109333.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    62. Oncogenic activation of the PI3-kinase p110ß isoform via the tumor-derived PIK3Cß(D1067V) kinase domain mutation. Oncogene. 2016 Mar 03; 35(9):1198-205. Pazarentzos E, Giannikopoulos P, Hrustanovic G, St John J, Olivas VR, Gubens MA, Balassanian R, Weissman J, Polkinghorn W, Bivona TG. PMID: 25982275.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    63. AXL receptor tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer (Auckl). 2015; 6:27-34. Okimoto RA, Bivona TG. PMID: 28210148.
      View in: PubMed   Mentions:
    64. The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors. Mol Cell Oncol. 2016 Jan; 3(1):e1021441. Lin L, Bivona TG. PMID: 27308535.
      View in: PubMed   Mentions:
    65. AXL mediates resistance to PI3Ka inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell. 2015 Apr 13; 27(4):533-46. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J. PMID: 25873175.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansAnimalsCells
    66. NF-?B-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015 Apr 07; 11(1):98-110. Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. PMID: 25843712.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    67. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells. PLoS One. 2015; 10(3):e0119832. Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona TG, Rho JK, Choi CM. PMID: 25780909.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    68. Adaptive stress signaling in targeted cancer therapy resistance. Oncogene. 2015 Nov 05; 34(45):5599-606. Pazarentzos E, Bivona TG. PMID: 25703329.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    69. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. PMID: 25665005.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansAnimalsCells
    70. YAP in MAPK pathway targeted therapy resistance. Cell Cycle. 2015; 14(12):1765-6. Flaherty KT, Wargo JA, Bivona TG. PMID: 26036142.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    71. RAS-MAPK in ALK targeted therapy resistance. Cell Cycle. 2015; 14(23):3661-2. Hrustanovic G, Bivona TG. PMID: 26654768.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    72. Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. J Transl Med. 2014 Dec 14; 12:355. Shen J, Wei J, Guan W, Wang H, Ding Y, Qian X, Yu L, Zou Z, Xie L, Costa C, Bivona T, Rosell R, Liu B. PMID: 25496700.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    73. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev. 2014 Sep; 40(8):990-1004. Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R. PMID: 24953979.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimals
    74. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A. 2014 Feb 18; 111(7):E748-57. Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG. PMID: 24550319.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    75. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 2014 Apr 01; 20(7):2001-10. Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. PMID: 24493829.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    76. Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. Hum Mutat. 2014 Mar; 35(3):318-28. Molina-Vila MA, Nabau-Moretó N, Tornador C, Sabnis AJ, Rosell R, Estivill X, Bivona TG, Marino-Buslje C. PMID: 24323975.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    77. Recent advances in personalized lung cancer medicine. Per Med. 2014; 11(3):309-321. Okimoto RA, Bivona TG. PMID: 25506379.
      View in: PubMed   Mentions: 9     Fields:    
    78. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013 Aug 24; 382(9893):720-31. Rosell R, Bivona TG, Karachaliou N. PMID: 23972815.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCells
    79. FGFR fusions in the driver's seat. Cancer Discov. 2013 Jun; 3(6):607-9. Sabnis AJ, Bivona TG. PMID: 23749526.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    80. Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther. 2013 Apr; 14(4):304-14. Hrustanovic G, Lee BJ, Bivona TG. PMID: 23358468.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    81. Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT. Clin Cancer Res. 2013 Jan 01; 19(1):3-5. Neel DS, Bivona TG. PMID: 23172883.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    82. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discov. 2012 Oct; 2(10):872-5. Blakely CM, Bivona TG. PMID: 23071030.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    83. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract. 2012; 2012:817297. Lin L, Bivona TG. PMID: 22970367.
      View in: PubMed   Mentions:
    84. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012 Jul 01; 44(8):852-60. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. PMID: 22751098.
      View in: PubMed   Mentions: 372     Fields:    Translation:HumansAnimalsCells
    85. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A. 2011 Nov 22; 108(47):19024-9. Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Huse J, Ganly I, Chan TA. PMID: 22065749.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    86. FAS and NF-?B signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011 Mar 24; 471(7339):523-6. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL. PMID: 21430781.
      View in: PubMed   Mentions: 147     Fields:    Translation:HumansCells
    87. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 2011 Mar 01; 17(5):1160-8. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL, Taron M. PMID: 21233402.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCells
    88. Analysis of K-Ras phosphorylation, translocation, and induction of apoptosis. Methods Enzymol. 2008; 439:87-102. Quatela SE, Sung PJ, Ahearn IM, Bivona TG, Philips MR. PMID: 18374158.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    89. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell. 2006 Feb 17; 21(4):481-93. Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, Yim D, Fein A, Pérez de Castro I, Li C, Thompson CB, Cox AD, Philips MR. PMID: 16483930.
      View in: PubMed   Mentions: 155     Fields:    Translation:HumansAnimalsCells
    90. Analysis of Ras activation in living cells with GFP-RBD. Methods Enzymol. 2006; 407:128-43. Bivona TG, Quatela S, Philips MR. PMID: 16757320.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    91. Analysis of Ras and Rap activation in living cells using fluorescent Ras binding domains. Methods. 2005 Oct; 37(2):138-45. Bivona TG, Philips MR. PMID: 16289969.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    92. Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII. J Biol Chem. 2005 Mar 25; 280(12):11413-21. Jordan JD, He JC, Eungdamrong NJ, Gomes I, Ali W, Nguyen T, Bivona TG, Philips MR, Devi LA, Iyengar R. PMID: 15657046.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    93. Membranes as messengers in T cell adhesion signaling. Nat Immunol. 2004 Apr; 5(4):363-72. Dustin ML, Bivona TG, Philips MR. PMID: 15052266.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    94. Identification of a Ras GTPase-activating protein regulated by receptor-mediated Ca2+ oscillations. EMBO J. 2004 Apr 21; 23(8):1749-60. Walker SA, Kupzig S, Bouyoucef D, Davies LC, Tsuboi T, Bivona TG, Cozier GE, Lockyer PJ, Buckler A, Rutter GA, Allen MJ, Philips MR, Cullen PJ. PMID: 15057271.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    95. Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus. Mol Cell Biol. 2004 Apr; 24(8):3485-96. Perez de Castro I, Bivona TG, Philips MR, Pellicer A. PMID: 15060167.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    96. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell. 2004 Feb 13; 13(3):341-55. Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG. PMID: 14967142.
      View in: PubMed   Mentions: 148     Fields:    Translation:AnimalsCells
    97. Rap1 up-regulation and activation on plasma membrane regulates T cell adhesion. J Cell Biol. 2004 Feb 02; 164(3):461-70. Bivona TG, Wiener HH, Ahearn IM, Silletti J, Chiu VK, Philips MR. PMID: 14757755.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansAnimalsCells
    98. Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK. J Biol Chem. 2003 Nov 21; 278(47):47038-45. Mohney RP, Das M, Bivona TG, Hanes R, Adams AG, Philips MR, O'Bryan JP. PMID: 12970366.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    99. Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1. Nature. 2003 Aug 07; 424(6949):694-8. Bivona TG, Pérez De Castro I, Ahearn IM, Grana TM, Chiu VK, Lockyer PJ, Cullen PJ, Pellicer A, Cox AD, Philips MR. PMID: 12845332.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansAnimalsCells
    100. Ras pathway signaling on endomembranes. Curr Opin Cell Biol. 2003 Apr; 15(2):136-42. Bivona TG, Philips MR. PMID: 12648668.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    101. Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol. 2002 May; 4(5):343-50. Chiu VK, Bivona T, Hach A, Sajous JB, Silletti J, Wiener H, Johnson RL, Cox AD, Philips MR. PMID: 11988737.
      View in: PubMed   Mentions: 231     Fields:    Translation:HumansAnimalsCells
    102. Toxoplasma gondii Rab5 enhances cholesterol acquisition from host cells. Cell Microbiol. 2002 Mar; 4(3):139-52. Robibaro B, Stedman TT, Coppens I, Ngô HM, Pypaert M, Bivona T, Nam HW, Joiner KA. PMID: 11906451.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells